Reduced ocular surface disease index (OSDI) scores in patients with isotretinoin treatment

Basit Öğe Kaydı
dc.authorid0000-0003-4391-2571
dc.contributor.authorÇağlar, İsmail Çağatay
dc.contributor.authorŞenel, Engin
dc.contributor.authorSabancılar, Emine
dc.contributor.authorDurmuş, Mustafa
dc.date.accessioned2019-05-10T09:39:35Z
dc.date.available2019-05-10T09:39:35Z
dc.date.issued2017
dc.departmentHitit Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü
dc.description.abstractTo evaluate the changes in ocular surface and functions of tear-film in patients treated with systemic isotretinoin, to assess diagnostic performance of ocular surface disease index (OSDI) test in the dry eye conditions in association with the use of isotretinoin, and to determine the correlation between all tear-film function tests, OSDI and the dose and duration of isotretinoin administration. One hundred and twenty eyes of 60 subjects treated with oral isotretinoin were enrolled. All patients underwent ophthalmic examination at the baseline and another examination during the course of treatment. Biomicroscopic ophthalmic examination of the meibomian glands, non-anesthetized Schirmer test, and tear film break-up time (BUT) were performed. Subjective ocular complaints were scored with an OSDI questionnaire. Average Schirmer scores were not significantly changed by isotretinoin treatment. There were significant differences in the average OSDI score, the average meibomian gland disease (MGD) grade and average BUT value of both eyes during the treatment compared with baseline values (p < 0.01). There was a statistically significant inverse correlation between MGD grade and BUT value. There was no significant correlation between BUT value, OSDI score, Schirmer score, MGD grade, the total and divided dose of isotretinoin and the duration of treatment. The follow-up time was 4.01 ± 1.3 months (range 1.5–6 months). Systemic isotretinoin treatment can cause alterations in the tear film and dry eye symptoms. The OSDI test can be used as a diagnostic test for patients receiving systemic isotretinoin treatment. © 2016, Springer Science+Business Media Dordrecht.
dc.identifier.citationÇağlar, Ç., Şenel, E., Sabancılar, E., Durmuş, M. (2017). Reduced ocular surface disease index (OSDI) scores in patients with isotretinoin treatment. International Ophthalmology, 37(1), 197-202.
dc.identifier.doi10.1007/s10792-016-0263-y
dc.identifier.endpage202en_US
dc.identifier.issn0165-5701
dc.identifier.issue1en_US
dc.identifier.scopusqualityQ2
dc.identifier.startpage197en_US
dc.identifier.urihttps://doi.org/10.1007/s10792-016-0263-y
dc.identifier.urihttps://hdl.handle.net/11491/733
dc.identifier.volume37en_US
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer Netherlands
dc.relation.ispartofInternational Ophthalmology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectBreak up Timeen_US
dc.subjectDry Eyeen_US
dc.subjectIsotretinoinen_US
dc.subjectMeibomian Gland Diseaseen_US
dc.subjectOcular Surface Disease Indexen_US
dc.subjectSchirmer Testen_US
dc.titleReduced ocular surface disease index (OSDI) scores in patients with isotretinoin treatment
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu